Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

PURPOSE: The extent of the survival benefit of augmentation therapy for alpha-1 antitrypsin deficiency (AATD) in individuals with advanced COPD is difficult to define. We performed a retrospective analysis using all available data from the observational registry of individuals with severe deficiency...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahaghi, Franck F, Monk, Richard, Ramakrishnan, Viswanathan, Beiko, Tatsiana, Strange, Charlie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721109/
https://www.ncbi.nlm.nih.gov/pubmed/33299307
http://dx.doi.org/10.2147/COPD.S263725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721109/
https://www.ncbi.nlm.nih.gov/pubmed/33299307
http://dx.doi.org/10.2147/COPD.S263725

Ejemplares similares